Pentahydroxy flavonoid isolated from *Madhuca indica* ameliorated adjuvant-induced arthritis via modulation of inflammatory pathways

Yongliang Tang1,2, Daotao Xie3, Wenqing Gong4, Hongtao Wu5 & Yi Qiang6*

Rheumatoid arthritis (RA) is an autoimmune disease associated with advanced joint dysfunction. *Madhuca indica* J. F. Gmel, from the family Sapotaceae, is an Indian medicinal plant reported to have an array of pharmacological properties. The aim of present investigation was to determine the anti-arthritic potential of an isolated phytoconstituent from methanolic leaf extract of *Madhuca indica* (MI-ALC) against FCA-induced experimental arthritis. Polyarthritis was induced in female rats (strain: Wistar) via an intradermal injection of FCA (0.1 mL) into the tail. Polyarthritis developed after 32 days of FCA administration. Then rats were treated orally with an isolated phytoconstituent from MI-ALC at doses of 5, 10, and 20 mg/kg. Findings suggested that High-Performance Thin-Layer Chromatography, Fourier-Transform Infrared Spectroscopy, and Liquid Chromatography-Mass Spectrometry spectral analyses of the phytoconstituent isolated from MI-ALC confirmed the structure as 3,5,7,3',4'-Pentahydroxy flavone (i.e., QTN). Treatment with QTN (10 and 20 mg/kg) showed significant (*p* < 0.05) inhibition of increased joint diameter, paw volume, paw withdrawal threshold, and latency. The elevated synovial oxidative stress (Superoxide dismutase, reduced glutathione, and malondialdehyde) and protein levels of Tumor necrosis factor-α (TNF-α) and Interleukin (ILs) were markedly (*p* < 0.05) reduced by QTN. It also effectively (*p* < 0.05) ameliorated cyclooxygenase-2 (COX-2), Nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-kβ) and its inhibitor-α (Ikβα), and ATP-activated P2 purinergic receptors (P2X7) protein expressions as determined by western blot analysis. In conclusion, QTN ameliorates FCA-induced hyperalgesia through modulation of elevated inflammatory release (NF-kβ, Ikβα, P2X7, and COX-2), oxido-nitrosative stress, and pro-inflammatory cytokines (ILs and TNF-α) in experimental rats.

Abbreviations

AIA  Adjuvant induced arthritis
ALT  Alanine transaminase
ALP  Alkaline phosphatase
AST  Aspartate aminotransferase
CRP  C-reactive protein
COX-2  Cyclooxygenase-2
ESR  Erythrocyte sedimentation rate
FCA  Freund’s complete adjuvant
GSH  Reduced glutathione
ILs  Interleukins

1Department of Orthopaedics, Xi’an Jiaotong University, Xi’an 710000, China. 2Department of Orthopaedics, Xi’an Central Hospital, Xi’an 710000, China. 3Department of Technology, Shaanxi Nuoxing Youchuang Medical Research Center, Xi’an 710032, China. 4Department of Ultrasound, Xijing Hospital, the Fourth Military Medical University, Xi’an 710032, China. 5Department of Gynecology, Xianyang Central Hospital, Xianyang 712000, China. 6Department of Orthopaedics, The Affiliated Hospital of Northwest University, Xi’an No. 3 Hospital, Xi’an 710018, China.*email: coke44pjy@sina.com
Rheumatoid arthritis (RA) is a complex, autoimmune, and inflammatory disorder associated with joint and synovial membrane inflammation, deformity, cartilage destruction, and pain, leading to loss of joint function and restricted limb motions\textsuperscript{12}. RA shows symmetrical progression affecting metacarpophalangeal and metatarso-phalangeal joints, proximal interphalangeal, ankle, and wrist\textsuperscript{3}. This immune-inflammatory arthritis affects about 1–2\%, i.e., nearly 20 million people worldwide, and the incidence is three times higher in women between the age of 40 and 50 years than men\textsuperscript{2,10}. It is associated with significantly higher lifetime costs along with a poor quality of life.

The use of NSAIDs (Non-steroidal anti-inflammatory drugs (including ibuprofen and acetylsalicylic acid)), DMARDs (disease-modifying anti-rheumatic drugs including methotrexate and Cyclosporin A), anti-CD20 and anti-TNFα (anti-tumor necrosis factor) (such as adalimumab, infliximab) are currently available therapies for management of RA\textsuperscript{4}. These treatments halt the progression of disease via suppression of immunological response. However, such treatment regimens provided symptomatic relief in a few patients and showed several adverse events, including gastrointestinal discomfort, increased cardiovascular risk, and nephrotoxicity\textsuperscript{1}. Thus, there is a need for conventional and alternative therapy with significant safety and efficacy. Numerous researchers have extensively utilized various animal models of Adjuvant induced arthritis (AIA) to analyze the efficiency of herbal medicinals. Polyarthritis induced by Freund’s complete adjuvant (FCA) is one of the most employed AIA animal models of arthritis that possess many common features with human rheumatoid arthritis\textsuperscript{1,2,7}.

\textit{Madhuca indica} J. F. Gmel (family Sapotaceae) is an Indian medicinal plant found in moist habitats and has been reported to have various pharmacological properties, such as anti-inflammatory, hepatoprotective, antiulcer, analgesic, anti-diabetic, cardioprotective, and wound healing\textsuperscript{8–14}. Literature survey revealed that \textit{Madhuca indica} contains chemical constituents such as quercitrin, quercetin, myricitrin, myricetin, erythritol, β-carotene xanthophylls, n-octacosanol, n-hexacosanol, palmitic acid, oleic acid, etc.\textsuperscript{15}. A recent study on Penta-hydroxy flavone, an isolated phytoconstituent from \textit{Madhuca indica} methanol extract, showed antiulcer activity via inhibition of cyclooxygenase (COX)-II, ILs, TNF-α, and iNOs\textsuperscript{13}. Researchers have reported that Penta-hydroxy flavone present in \textit{Madhuca indica} modulated expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ) and nuclear factor-like 2 (Nrf2) as well as attenuated elevated oxidative stress to exert its cardioprotective activity\textsuperscript{13}. Traditionally, \textit{Madhuca indica} has been prescribed for management of arthritis and associated pain\textsuperscript{10,17}. Additionally, a study reported the anti-inflammatory potential of \textit{Madhuca longifolia} ethanolic extract in experimental rats\textsuperscript{16}. Our preliminary study (unpublished) suggested that \textit{Madhuca indica} leaves methanolic extract exhibits potent anti-arthritic activity. However, to the best of our knowledge, the potential phytoconstituents responsible for its anti-arthritic activity remain to be determined. Given this premise, the present investigation was undertaken with the objective of investigating the anti-arthritic activity of a phytoconstituent isolated from the leaves of \textit{Madhuca indica} methanolic extract against FCA-induced experimental arthritis.

**Material and methods**

**Animals.** Wistar rats (Adult female, 150–180 g) were procured from the animal house of Xi’an Central Hospital. The rats were maintained in-house at 24 ± 1 °C, 12 h:12 h dark-light cycle, with standard pellet feed and filtered water during the experimental time of 0800 h and 1700 h in quiet laboratory environment. The Xi’an Central Hospital’s Institutional animal ethics committee approved all the experimental research protocols (no. XCH202013771).

**Chemicals and reagents.** Reagents used during the study included rat specific ELISA (enzyme-linked immunosorbent assay) kit for ILs (IL-1β, and IL-6) and TNF-α (Bethyl Laboratories Inc., Montgomery, TX, USA), primary antibodies of NF-kβ, Ikβα, COX-2, P2X7, and GAPDH (Abcam, Cambridge, MA, USA), FCA (Sigma Aldrich, St. Louis, USA), microliter syringe (Hamilton, Bonaduz, Switzerland), ethyl acetate, methanol, formic acid, toluene (Merck Life Science Pvt Ltd, India), and high-performance thin-layer chromatography (HPTLC) (Linomat V, Camag, Muttenz, Switzerland). Additionally, rat-specific tumor necrosis factor-α (TNF-α), Interleukin (IL)-1β, and IL-6 enzyme-linked immunosorbent assay (ELISA) kit were obtained from Bethyl Laboratories Inc. (Montgomery, TX, USA).

**QTN (3,5,7,3′,4′-Penta-hydroxy flavone) isolation and characterization.** Purification, isolation, and characterization of QTN (3,5,7,3′,4′-Penta-hydroxy flavone) was performed according to a method reported elsewhere\textsuperscript{18}. Briefly, air-dried powdered leaves of \textit{Madhuca indica} J. F. Gmel. (500 g) was extracted with methanol (MI-ALC), and initial phytochemical screening was performed to identify various phytochemicals such as flavonoids, alkaloids, steroid & phenols, etc.\textsuperscript{14}. Further fractionation of MI-ALC was performed with chloroform and mixed with acetone (70 mL) for column chromatography analysis. Elution was carried out with mobile condi-
Adjuvant-induced polyarthritis (AIA). FCA (0.1 mL, intradermal) was injected into the tail of the rats to induce AIA in female rats (150–180 g; 5 groups, i.e., group II to VI, n = 18 each group)\(^\text{19}\). Following the injection, 32 days were allowed for development of arthritis. A separate group of rats (group I, n = 18) was maintained as normal and did not receive FCA. After the development of AIA (32 days), animals received either dimethyl sulfoxide (DMSO) (0.5%, 10 mg/kg, p.o. in group I and II) or leflunomide (10 mg/kg in 0.5% DMSO, as a standard in group III) or QTN (5, 10 and 20 mg/kg in 0.5% DMSO in group IV to VI) for the next 28 days\(^\text{14}\). A solution of leflunomide or QTN was freshly prepared daily in 0.5% DMSO and administered to rats by oral gavage (1 mL) according to their dose based on body weight of rats.

Plethysmometer (UGO Basile Italy) was used to determine paw volume\(^\text{30}\). Pain latency against mechanical hyperalgesia (paw withdrawal threshold) was determined by using Randall-Selitto, i.e., paw pressure test (UGO Basile Model 7200) as well as von Frey hair application\(^\text{30}\). Hargreaves apparatus (UGO Basile, SRL Biological Research Apparatus, Italy) was used to determine paw withdrawal latency\(^\text{21,12}\).

Biochemical estimation. On the last day of study (day 60), rats were anesthetized with ether and retro-orbital plexus was used to withdraw blood. After blood withdrawal, rats were sacrificed by cervical dislocation. Immediately synovial tissues were isolated and stored at −70 °C. Levels of ESR (Erythrocyte Sedimentation Rate), CRP (C-reactive protein), WBC (White blood cell), Hb (hemoglobin), RBC (Red blood cell), and PLT (platelets) were estimated in blood\(^\text{50}\), whereas turbidity, albumin, AST (aspartate transaminase), ALP (alkaline phosphatase), ALT (alanine transaminase), and TC (total cholesterol) were measured in serum using reagent kits (Accurex Biomedical Pvt. Ltd., Mumbai, India)\(^\text{35}\).

Determination of tissue oxido-nitrosative stress. Tris–HCl buffer (0.1 M, pH 7.4) was used to prepare homogenates of synovial tissue, and the supernatant was used to determine oxido-nitrosative stress (n = 5–6), i.e., MDA (lipid peroxidation), GSH (reduced glutathione), SOD (superoxide dismutase) and NO (nitric oxide) according to previously described method\(^\text{11}\).

Determination of synovial pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) levels. Pro-inflammatory cytokine levels, i.e., TNF-α, IL-1β, and IL-6 of synovial tissue (n = 5–6) were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol (Bethyl Laboratories Inc., Montgomery, TX, USA). TNF-α, IL-1β, and IL-6 were determined from a standard curve for the combination of these cytokines. The concentrations were expressed as pg/mg of protein. Briefly, the quantifications of TNF-α, IL-1β, and IL-6 were done in accordance to the protocol provided with Bethyl Laboratories Inc. Rat TNF-α, IL-1β, and IL-6 immunoassay kit. Rat TNF-α, IL-1β, and IL-6 immunoassay was a 4.5 h solid-phase ELISA designed to measure rat TNF-α, IL-1β, and IL-6 levels. The assay employed a sandwich enzyme immunoassay principle. A monoclonal antibody specific to rat TNF-α, IL-1β, and IL-6 was pre-coated on the microplates. Standards, control, and samples were pipetted into the wells, and the assay was set up in duplicate. The optical density was read at 405 nm.

The protein expressions of COX-2, Ikβα, NF-κβ, and P2X7. The protein expressions of COX-2, Ikβα, NF-κβ, and P2X7 in synovial tissue (n = 4) were determined using Western blot analysis according to a method reported elsewhere\(^\text{44}\). Briefly, synovial tissue was sonicated in tissue protein extraction reagent (Thermo Fisher Scientific, Inc.). The lysates were centrifuged at 10,000 x g for 10 min at 4 °C. Protein concentration was determined using a Bicinchoninic Acid (BCA) assay kit (Beyotime Shanghai, China) on ice for 30 min. Equal amounts of extracted protein samples (50 μg) were separated by 10% SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% non-fat dry milk at 37 °C for 1 h and incubated overnight at 4 °C with the primary antibodies that recognized COX-2, Ikβα, NF-κβ, P2X7 and GAPDH. Anti-rabbit horseradish-linked IgG was used as the secondary antibody, which was incubated at 37 °C for 2 h. Protein bands were visualized using Chemiluminescent kit (Bio-Rad Laboratories, Inc.) and GAPDH served as the loading control.
Histopathology of tibiotarsal joint. Ankle joints from three rats of each group were separated, cleaned, washed in cold physiological saline, and preserved in 10% formaldehyde solution until histopathological studies. At the time of staining, sections of tibiotarsal joints were cut (5 μm thickness) with the help of microtome, deparaffinated, and stained using hematoxylin and eosin (H and E) stain. The specimens were mounted on slides using Distrene Phthalate Xylene (DPX). Sections were examined under a light microscope (Olympus DP71, DP-BSW Ver.03.03, Olympus Medical Systems India Private Limited, India) to obtain a general impression of the histopathological features of the specimen and infiltration of cells in epithelium and sub-epithelium. The intensity of histological aberrations in the tibiotarsal joint was graded as Grade 0 (not present); Grade 1 (slight/minimal); Grade 2 (mild); Grade 3 (moderate) or Grade 4 (severe) as described in the literature25.

Statistical analysis. GraphPad Prism 5.0 software (GraphPad, San Diego, CA) was used to perform data analysis. Data are expressed as mean ± standard error mean (SEM) and analyzed using One-Way ANOVA followed by Tukey’s multiple range post hoc analysis (for parametric tests including body weight, joint diameter, paw volume, paw withdrawal latency, paw withdrawal threshold, serum AST, ALT, ALP, albumin, CRP, rheumatoid factor, hematological parameters, ESR, antioxidant parameters, cytokines levels and protein expressions (COX-2, IkBα, NF-κB, and P2X7) or Kruskal–Wallis test for post hoc analysis (non-parametric tests, i.e., histopathology score). A value of p < 0.05 was considered to be statistically significant.

Ethical approval. The research protocol (no. XCH202013771) was approved by the Institutional animal ethics committee (IAEC) of Xi’an Central Hospital. Guidelines outlined in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARRIVE (Animal Research: Reporting of In vivo Experiments) guidelines (http://www.nc3rs.org/ARRIVE) were followed to perform all the experiments.

Results

Compound D3 Isolation and characterization. In the yield of MI-ALC, its fractions D and D 3 were 26.8%, namely 5.42 g, and 30.8 mg. HPTLC linearity profile of marker compound (quercetin) and QT from 50 to 500 ng/μl at 370 nm are shown in Supplementary File 1A and B. The results of regression analysis of the calibration curves showing the correlation coefficient (0.980), intercept (− 550.1), and slope (40.50) are given in Supplementary File 1C. The UV spectrum of the test sample is superimposable with that of standard quercetin, indicating the purity of the peak (Supplementary File 1D).

Figure 1A depicts chromatograph of marker compound (i.e., quercetin), and Fig. 1B depicts chromatogram of isolated fraction QT. QTN is an amorphous powder with a melting point of 307–309 °C. FTIR spectrum of compound QTN is shown in Supplementary File 1E. The QTN showed a molecular ion peak at m/z 302 in the LC–MS spectrum, suggesting molecular formula C15H10O7 (Supplementary File 1F) and 3,5,7,3′,4′-Pentahydroxy flavone as the chemical structure which corroborated reported literature (Supplementary File 1F)14.

Body weight, paw volume, joint diameter, paw withdrawal threshold, and latency. Body weight markedly decreased (p < 0.05), whereas joint diameter, paw volume, paw withdrawal threshold, and latency increased significantly (p < 0.05) in AIA control rats compared to normal rats. Treatment with leflunomide (10 mg/kg) effectively inhibited (p < 0.05) FCA-induced alterations in body weight, paw volume, joint diameter, paw withdrawal threshold, and latency compared to AIA control rats. QTN (10 and 20 mg/kg) treatment significantly decreased (p < 0.05) body weight and significantly decreased (p < 0.05) paw volume, joint diameter, paw withdrawal threshold, and latency when compared with AIA control rats. (Table 1 and Fig. 2).

AST, ALT, ALP, albumin, CRP, and rheumatoid factor. When compared to normal rats, serum ALT, AST, ALP, and CRP markedly (p < 0.05) increased, whereas serum albumin level significantly (p < 0.05) decreased in the AIA control rats. Leflunomide (10 mg/kg) treatment effectively (p < 0.05) increased albumin level in serum whereas it markedly (p < 0.05) reduced levels of ALT, AST, ALP and CRP in serum compared to AIA control rats. The FCA-induced alterations in serum AST, ALT, ALP, and albumin levels were significantly (p < 0.05) attenuated by QTN (10 and 20 mg/kg) when compared with AIA control. These alterations in levels of serum AST, ALT, ALP, albumin, and CRP were more effectively (p < 0.05) attenuated by leflunomide (10 mg/kg) when compared to QTN treatment. (Table 2).

The subplantar administration of FCA resulted in a marked increase (p < 0.05) in the rheumatoid factor in AIA control rats compared to normal rats. As compared to AIA control rats, leflunomide (10 mg/kg) and QTN (10 and 20 mg/kg) treatment significantly decreased (p < 0.05) rheumatoid factor. (Table 2).

Hematological parameters and ESR levels. A significant decrease (p < 0.05) in RBCs and Hb levels, whereas a marked increase (p < 0.05) in WBCs, platelet, and ESR levels were observed in AIA control rats when compared with normal rats. Treatment with Leflunomide (10 mg/kg) effectively ameliorated (p < 0.05) hematological and ESR variations when compared with AIA control rats. QTN (10 and 20 mg/kg) significantly increased (p < 0.05) levels of RBCs and Hb whereas effectively reduced (p < 0.05) WBCs, platelet and ESR levels when compared with AIA control rats. However, leflunomide (10 mg/kg) more significantly (p < 0.05) attenuated FCA-induced hematological and ESR variations as compared to QTN treatment. (Table 3).

Synovial oxido-nitrosative stress. Synovial GSH and SOD markedly decreased (p < 0.05), whereas NO and MDA levels level in serum whereas it markedly (p < 0.05) reduced levels of ALT, AST, ALP and CRP in serum compared to AIA control rats. The FCA-induced alterations in serum AST, ALT, ALP, and albumin levels were significantly (p < 0.05) attenuated by QTN (10 and 20 mg/kg) when compared with AIA control. These alterations in levels of serum AST, ALT, ALP, albumin, and CRP were more effectively (p < 0.05) attenuated by leflunomide (10 mg/kg) when compared to QTN treatment. (Table 2).

The subplantar administration of FCA resulted in a marked increase (p < 0.05) in the rheumatoid factor in AIA control rats compared to normal rats. As compared to AIA control rats, leflunomide (10 mg/kg) and QTN (10 and 20 mg/kg) treatment significantly decreased (p < 0.05) rheumatoid factor. (Table 2).

Hematological parameters and ESR levels. A significant decrease (p < 0.05) in RBCs and Hb levels, whereas a marked increase (p < 0.05) in WBCs, platelet, and ESR levels were observed in AIA control rats when compared with normal rats. Treatment with Leflunomide (10 mg/kg) effectively ameliorated (p < 0.05) hematological and ESR variations when compared with AIA control rats. QTN (10 and 20 mg/kg) significantly increased (p < 0.05) levels of RBCs and Hb whereas effectively reduced (p < 0.05) WBCs, platelet and ESR levels when compared with AIA control rats. However, leflunomide (10 mg/kg) more significantly (p < 0.05) attenuated FCA-induced hematological and ESR variations as compared to QTN treatment. (Table 3).

Synovial oxido-nitrosative stress. Synovial GSH and SOD markedly decreased (p < 0.05), whereas NO and MDA levels level in serum whereas it markedly (p < 0.05) reduced levels of ALT, AST, ALP and CRP in serum compared to AIA control. These alterations in levels of serum AST, ALT, ALP, albumin, and CRP were more effectively (p < 0.05) attenuated by leflunomide (10 mg/kg) when compared to QTN treatment. (Table 2).
decreased effectively ($p < 0.05$) in synovial fluid when compared with AIA control rats. Similarly, QTN (10 and 20 mg/kg) effectively attenuated ($p < 0.05$) FCA-induced increased synovial oxido-nitrosative stress when compared with AIA control rats. However, elevated MDA and decreased GSH levels were more effectively ($p < 0.05$) attenuated by QTN (20 mg/kg) when compared with leflunomide (10 mg/kg). (Table 4).

**Synovial ILs (IL-1β, and IL-6) and TNF-α protein levels.** Intrapitoneal administration of FCA resulted in a significant increase ($p < 0.05$) in ILs (IL-1β, and IL-6) and TNF-α protein levels in the synovial tis-

---

**Figure 1.** HPTLC profile of quercetin (A) and HPTLC profile of chloroform fraction D (QTN) of MI-ALC (B). Eluent–toluene: ethyl acetate: formic acid (6: 3.5: 0.5) (v/v/v). The detection was at 370 nm.

---

**Table 1.** Effects of QTN on FCA-induced alterations in body weight, change in joint diameter, change in paw volume, paw withdrawal latency, and paw withdrawal threshold (Von-Frey hair and paw pressure test). Values in parentheses indicate a dose in mg/kg ($n = 6$). Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test. For comparison with AIA-control group: *$p < 0.05$, comparison with normal group: #$p < 0.05$ and comparison with one another: @$p < 0.05$. AIA adjuvant-induced arthritis, LF leflunomide, QTN 3,5,7,3,4′-pentahydroxy flavone, AUC area under curve.
sue of AIA control rats when compared with normal rats. Leflunomide (10 mg/kg) markedly inhibited \((p<0.05)\) FCA-induced increased synovial ILs (IL-1β, and IL-6) and TNF-α protein levels as compared to AIA control rats. QTN (10 and 20 mg/kg) also effectively decreased \((p<0.05)\) elevated synovial ILs (IL-1β, and IL-6) and TNF-α protein levels when compared with AIA control rats. The elevated synovial TNF-α and IL-6 protein levels were more effectively \((p<0.05)\) attenuated by leflunomide (10 mg/kg) when compared with QTN. (Table 4).

**Synovial COX-2, IkBα, NF-kβ, and P2X7 protein expressions.** The protein expressions of COX-2, IkBα, NF-kβ, and P2X7 in synovial tissues of AIA control rats was up-regulated markedly \((p<0.05)\) after administration of FCA when compared with normal rats. Leflunomide (10 mg/kg) effectively \((p<0.05)\) down-regulated protein expressions of COX-2, IkBα, NF-kβ, and P2X7 in synovial tissues when compared to AIA control rats. Moreover, QTN (10 and 20 mg/kg) also effectively \((p<0.05)\) inhibited FCA-induced up-regulated protein expressions of COX-2, IkBα, NF-kβ, and P2X7 in synovial tissues when compared with AIA control rats. QTN (20 mg/kg) showed more effective \((p<0.05)\) down-regulation in the protein expression of P2X7 in synovial tissues as compared to leflunomide (10 mg/kg). (Fig. 3 and Supplementary File 1G-K).
Histopathology of the tibiotarsal joint. FCA administration resulted in marked histological aberrations in the tibiotarsal joint of AIA control rats reflected by an effective increase ($p < 0.05$) in inflammatory infiltration, synovial proliferation, cartilage erosion, and pannus formation (Fig. 4B) when compared with normal rats. Whereas, tibiotarsal joint of normal rats showed minimal inflammatory infiltration, synovial proliferation, and pannus formation (Fig. 4A). Leflunomide (10 mg/kg) treatment effective inhibited ($p < 0.05$) FCA-induced histological aberrations in tibiotarsal joint (Fig. 4C) when compared with AIA control rats. However, compared with AIA control rats, QTN (5 mg/kg) failed to produce any marked protection against histological aberrations induced by FCA in the tibiotarsal joint (Fig. 4D). But QTN (10 and 20 mg/kg) effectively decreased ($p < 0.05$) inflammatory infiltration, synovial proliferation, and pannus formation (Fig. 4E,F) when compared with AIA control rats. (Fig. 4G).

**Table 2.** Effects of QTN on FCA-induced alterations in serum AST, ALT, ALP, albumin, CRP, and rheumatoid factor levels. Values in parentheses indicate a dose in mg/kg (n = 6). Data were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. For comparison with AIA-control group: *$p < 0.05$, comparison with normal group: $p < 0.05$ and comparison with one another: $p < 0.05$. AIA, adjuvant-induced arthritis, LF, leflunomide, QTN, 3,5,7,3′,4′-pentahydroxy flavone, AST, aspartate aminotransferase, ALT, alanine transaminase, CRP, c-reactive protein.

| Treatment | AST (U/mL) | ALT (U/mL) | Alkaline phosphatase (U/L) | Albumin (g/dl) | CRP (mg/L) | Rheumatoid factor (IU/mL) |
|-----------|------------|------------|---------------------------|---------------|------------|--------------------------|
| Normal    | 39.95 ± 3.02 | 33.78 ± 1.83 | 69.24 ± 5.42 | 6.52 ± 0.38 | 0.99 ± 0.04 | 0.00 ± 0.00 |
| AIA Control | 122.90 ± 2.84 | 165.80 ± 7.45 | 435.00 ± 11.81 | 2.00 ± 0.22 | 7.65 ± 0.34 | 60.25 ± 1.55 |
| LF (10)   | 59.56 ± 3.74 | 51.11 ± 5.14 | 136.7 ± 5.99 | 6.25 ± 0.31 | 2.60 ± 0.24 | 38.58 ± 1.47 |
| QTN (5)   | 118.70 ± 4.26 | 146.60 ± 3.80 | 433.20 ± 6.50 | 2.25 ± 0.26 | 7.02 ± 0.18 | 56.96 ± 1.61 |
| QTN (10)  | 88.02 ± 3.71 | 90.45 ± 3.86 | 274.60 ± 12.82 | 4.05 ± 0.21 | 4.74 ± 0.27 | 47.86 ± 1.74 |
| QTN (20)  | 62.75 ± 1.42 | 52.28 ± 3.82 | 139.30 ± 7.38 | 5.78 ± 0.22 | 2.67 ± 0.13 | 38.88 ± 0.97 |

**Table 3.** Effects of QTN on FCA-induced alterations in hematological parameters and ESR level. Values in parentheses indicate a dose in mg/kg (n = 6). Data were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. For comparison with AIA-control group: *$p < 0.05$, comparison with normal group: $p < 0.05$ and comparison with one another: $p < 0.05$. AIA, adjuvant-induced arthritis, LF, leflunomide, QTN, 3,5,7,3′,4′-pentahydroxy flavone, RBC, red blood cells, WBC, white blood cells, ESR, erythrocyte sedimentation rate.

| Treatment | RBC (X 10⁶/µL) | WBC (X 10³/µL) | Hb (g/dL) | Platelets (X 10⁹/L) | ESR (mm) |
|-----------|----------------|-----------------|----------|---------------------|---------|
| Normal    | 5.55 ± 0.23    | 5.78 ± 0.30     | 15.83 ± 0.52 | 912.80 ± 40.47 | 3.64 ± 0.23 |
| AIA Control | 1.95 ± 0.17    | 12.45 ± 0.41    | 9.81 ± 0.53 | 1658.00 ± 35.94 | 14.69 ± 0.27 |
| LF (10)   | 4.91 ± 0.26    | 6.84 ± 0.29     | 15.41 ± 0.73 | 1013.00 ± 37.21 | 9.97 ± 0.44 |
| QTN (5)   | 2.02 ± 0.21    | 11.92 ± 0.25    | 10.10 ± 0.43 | 1633.00 ± 38.45 | 14.30 ± 0.44 |
| QTN (10)  | 2.94 ± 0.24    | 9.55 ± 0.25     | 12.16 ± 0.60 | 1453.00 ± 37.97 | 12.63 ± 0.42 |
| QTN (20)  | 4.45 ± 0.20    | 6.96 ± 0.28     | 15.39 ± 0.33 | 1048.00 ± 27.22 | 10.19 ± 0.43 |

**Table 4.** Effects of QTN on FCA-induced alterations in antioxidant parameters in synovial tissues. Values in parentheses indicate a dose in mg/kg (n = 5–6). Data were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. For comparison with AIA-control group: *$p < 0.05$, comparison with normal group: $p < 0.05$ and comparison with one another: $p < 0.05$. AIA, adjuvant-induced arthritis, LF, leflunomide, QTN, 3,5,7,3′,4′-pentahydroxy flavone, SOD, superoxide dismutase, GSH, glutathione peroxidase, MDA, malondialdehyde, NO, Nitric oxide.

| Treatment | SOD (U/mg of protein) | GSH (µg/mg of protein) | MDA (nM/mg of protein) | NO (µg/mL) |
|-----------|-----------------------|-----------------------|------------------------|-----------|
| Normal    | 5.75 ± 0.27           | 81.76 ± 2.57          | 0.97 ± 0.11            | 116.50 ± 13.63 |
| AIA Control | 3.24 ± 0.26           | 52.20 ± 3.35          | 2.46 ± 0.09            | 519.00 ± 11.21 |
| LF (10)   | 4.55 ± 0.25           | 68.51 ± 2.09          | 1.67 ± 0.13            | 168.80 ± 14.86 |
| QTN (5)   | 3.31 ± 0.24           | 55.80 ± 1.67          | 2.39 ± 0.09            | 486.10 ± 13.86 |
| QTN (10)  | 3.99 ± 0.27           | 63.13 ± 2.21          | 1.95 ± 0.12            | 400.40 ± 13.97 |
| QTN (20)  | 4.55 ± 0.24           | 69.32 ± 1.52          | 1.62 ± 0.13            | 284.00 ± 14.63 |
**Discussion**

*Madhuca indica* is a traditional medicine rich in various phytoconstituents dominant with the presence of flavonoids. It has been widely used to manage various inflammatory disorders due to its inhibitory potential against histamine, serotonin, prostaglandin, and COX-2\(^1\). In the present study, we have assessed the anti-arthritic effect of an isolated phytoconstituent (3,5,7,3',4'-pentahydroxy flavone, i.e., QTN) from *Madhuca indica* Leaves on female Wistar rats after subplantar administration of FCA. The findings of the present investigation suggested that methanolic extract from *Madhuca indica* leaves exhibit anti-arthritic activity and its phytoconstituent 3,5,7,3',4'-pentahydroxy flavone (i.e., QTN) is responsible for its anti-arthritic potential. Furthermore, QTN exerts its anti-arthritic potential via attenuation of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), oxidant stress, and NF-κβ, Ikβα, COX-2, and P2X7 expressions. Results of present investigation are in line with the findings of previous investigators where administration of Pentaflavone flavone, i.e., quercetin ameliorated collagen-induced arthritis\(^2\) and adjuvant arthritis\(^3\) in experimental animal models.

---

**Figure 3.** Effects of QTN on FCA-induced alterations in protein expression of NF-κβ p65 (A), p-Ikβα (B), COX-2 (C), and P2X7 (D) in synovial tissues. Data are expressed as mean ± SEM (n = 4) and analyzed by one-way ANOVA followed by Tukey’s multiple range test. For comparison with AIA-control group: *p < 0.05, comparison with normal group: *p < 0.05 and comparison with one another: *p < 0.05. Normal group protein expression (lane 1); AIA control group protein expression (lane 2); Leflunomide group protein expression (lane 3) and QTN (5, 10, and 20 mg/kg) group protein expression (lane 4–6). AIA adjuvant-induced arthritis, LF leflunomide, QTN 3,5,7,3',4'-pentahydroxy flavone, NF-κβ nuclear factor kappa beta, Ikβα nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor-a, COX-2 cyclooxygenase-2, P2X7 ATP-activated P2 purinergic receptors.
Previous studies showed that elevated paw thickness is an evidence of arthritis induction. Determination of paw thickness using a plethysmometer is a well-established and standardized method during AIA-induced arthritis. In the present study, the inflamed rat's edematous hind paw was estimated using a plethysmometer. It was further subjected to a constant force to assess the pain threshold that was examined by the Randall–Selitto assay method. Treatment with QTN significantly decreased paw thickness, which might be due to inflammatory mediator inhibition suggesting its anti-inflammatory property against FCA-induced arthritis. This potential of cytokine blockage in pain nervous fibers by QTN might be responsible for increased pain threshold testifying its analgesic effect. The presence of flavonoid moiety in the methanolic extract of *Madhuca indica* could be responsible for its anti-inflammatory, analgesic, and anti-nociceptive activities. The findings of the current study corroborate the results of earlier investigators where *Madhuca indica* phytoconstituents showed anti-inflammatory potential via reduction of TNF-α and IL-1β.

Oxidative stress plays a central role in the activation and maintenance of painful arthritis. It has been reported that increased production of ROS (reactive oxygen species) such as hydroxyl, hydrogen peroxide, and superoxide radicals contribute to elevated oxidative stress. This elevated oxidative stress further decreased protective antioxidant moieties (GSH and SOD) that caused elevation of MDA (lipid peroxidation), thus damaging biomembrane macromolecules. The FCA administration caused a marked reduction in synovial GSH and SOD, whereas the MDA level increased effectively. However, treatment with QTN significantly attenuated FCA-induced decreased GSH and SOD in the synovial tissue suggesting its antioxidant potential that might support the anti-arthritic mechanism. These findings are in accordance with the results of an earlier study where QTN isolated from *Madhuca indica* was shown to exert its potential via attenuation of oxidative stress.

Numerous researchers have suggested that the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) plays a vital role in the induction and maintenance of immune-inflammatory disease modulation of various biomolecules such as COX-2 and pro-inflammatory cytokines. During the resting state, the NF-κB remains unstimulated and retains an inactive state in the cytoplasm. Whereas, IκB kinase, which is an enzyme complex, plays an essential role in the upstream NF-κB signal transduction pathway, and its phosphorylated activation leads to subsequent ubiquitination and degradation of 26S proteasome. This cascade leads to NF-κB translocation to the nucleus from the cytoplasm, where it modulates the expression of various genes, including pro-inflammatory cytokines. In the present investigation, activated expressions of IκBα and NF-κB were found to be significantly up-regulated in synovial of AIA control rats after administration of FCA whereas QTN treatment significantly down-regulated these expressions of pro-inflammatory cytokines via attenuation of IκBα phosphorylation and thus inactivation of NF-κB.

Purinergic Receptor-X 7 (P2X7), a protein-coding gene from the purinoceptors family, has been suggested to play a central role in the induction and maintenance of an array of diseases associated with bone cartilage such as RA. It is known to play a vital role in bone remodeling via activation of various mediators, including IL-1β and prostaglandins, in the synovial fluid. It has been suggested that activation of ectonucleotidases degrade extracellular ATP, which results in the formation of active molecules such as adenosine or pyrophosphates. These active molecules further promote the activation of alternative macrophages and thus initiate the release of pro-inflammatory signaling. Therefore, extracellular metabolism of ATP by P2X7 modulates the sequence of inflammatory influx and thus initiates the pathogenesis of RA. In this view, inhibition of P2X7 receptor activation would be beneficial for the management of RA. In the current investigation, treatment with QTN significantly inhibits P2X7 activation, which might reduce the bone and cartilage damage in RA.
Recently an array of isolated phytoconstituents from herbal origin have been implicated in the management of arthritis clinically. Studies have investigated the potential of various moieties such as Pycnogenol from *Pinus pinaster* Aiton, Curcuminoids from *Curcuma longa*, Bromelain from *Ananas comosus*, etc. for the symptomatic relief of RA. Furthermore, a researcher suggested that a moiety bearing carbonyl group at C-4 and a hydroxyl group at C-3 or C-5 in their structure have chelation ability with metal ions, helpful in exerting its antioxidant property. In the current study, an isolated moiety from methanolic extract of leaves of *Madhuca indica*, i.e., QTN (3,5,7,3',4'-Pentahydroxy flavone) also bears such hydroxyl and carbonyl groups in its structure, indicating promising antioxidant potential. Thus, QTN can be considered as a potential therapeutic moiety for the management of RA clinically.

**Conclusion**

A phytoconstituent isolated from methanolic extract *Madhuca indica* leaves, identified as 3,5,7,3',4'-Pentahydroxy flavone (i.e., QTN), exhibits anti-arthritic activity. QTN ameliorates FCA-induced hyperalgesia through attenuation of elevated inflammatory mediators (NF-κB, Ikκα, COX-2, and P2X7), oxido-nitrosative stress, and pro-inflammatory cytokines (ILs and TNF-α) experimental rats.

**Data availability**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Received: 17 April 2021; Accepted: 2 August 2021
Published online: 09 September 2021

**References**

1. Dudics, S. et al. Natural products for the treatment of autoimmune arthritis: their mechanisms of action, targeted delivery, and interaction with the host microbiome. Int. J. Mol. Sci. [https://doi.org/10.3390/ijms19092508] (2018).
2. Guo, Q. et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 6, 15–15. [https://doi.org/10.1038/s41413-018-0016-9] (2018).
3. Ghosh, P. et al. Determination of clinical outcome and pharmacoeconomics of anti-rheumatoid arthritis therapy using CDAI, EQ–5D–3L and EQ–VAS as indices of disease amelioration. Asian Pac. J. Trop. Dis. 2, 5671–5678 (2012).
4. Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360–1372. [https://doi.org/10.1001/jama.2018.13103] (2018).
5. Linos, A., Worthington, J. W., O’Fallon, W. M. & Kurland, L. T. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am. J. Epidemiol. 111, 87–98. [https://doi.org/10.1093/oxfordjournals.aje.a112878] (1980).
6. Chen, Z., Bozea, A., Ramming, A. & Schett, G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol. 15, 9–17. [https://doi.org/10.1038/s41584-018-0109-2] (2019).
7. Honmore, V. S. et al. Diarylheptanoid, a constituent isolated from methanol extract of *Alpinia officinarum* attenuates TNF-alpha level in Freund’s complete adjuvant-induced arthritis in rats. J. Ethnopharmacol. 229, 233–245. [https://doi.org/10.1016/j.jep.2018.10.019] (2019).
8. Shekhawat, N. & Vijayvergia, R. Investigation of anti-Inflammatory, analgesic and antipyretic properties of *Madhuca indica* Gmel. Int. J. Mol. Med. Adv. Sci. 6, 36–30 (2010).
9. Khan, S. et al. Antiinflammatory activity studies with methanol extract of *Madhuca indica* JF Gmel leaves and *Paederia foetida* L. stems in mice. Adv. Nat. Appl. Sci. 5, 122–126 (2011).
10. Prashanth, S., Kumar, A. A., Madhu, B. & Kumar, Y. P. Antiinflammatory and antioxidant activity of ethanolic extract of *madhuca longifolia* bark. Int. J. Pharm. Sci. Res. 5, 89–94 (2014).
11. Kumar, K. P. et al. Screening of *Madhuca indica* for antiinflammatory activity in streptozotocin and streptozotocin–nicotinamide induced diabetic rats. J. Pharm. Biomed. 12, 1073–1077 (2011).
12. Anu, C., Anil, B. & Pandurangan, A. Anti diabetic activity of methanolic extract of *Madhuca indica* on normal and streptozotocin induced diabetic rats. Int. J. Pharm. Res. Dev. 3, 13–18 (2011).
13. Mohod, S. M., Kandhare, A. D. & Bodhankar, S. L. Gastroprotective potential of Pentahydroxy flavone isolated from *Madhuca indica* extract against acetic acid-induced ulcer in rats: the role of oxido-inflammatory and prostaglandins markers. J. Ethnopharmacol. 182, 150–159 (2016).
14. Mukherjee, A. A., Kandhare, A. D. & Bodhankar, S. L. Elucidation of protective efficacy of pentahydroxy flavone isolated from *Madhuca indica* against arsenite-induced cardiomyopathy: role of Nrf-2, PPAR-gamma, c-fos and c-jun. Environ. Toxicol. Pharmacol. 56, 172–185. [https://doi.org/10.1016/j.etap.2017.08.027] (2017).
15. Chatterjee, A. et al. Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. Acta Biochim. Biophys. Sin. 44, 565–576. [https://doi.org/10.1093/abbs/gmso34] (2012).
16. Patel, P. K., Prajapati, N. K. & Dubey, B. *Madhuca indica*: a review of its medicinal property. Int. J. Pharm. Sci. Res. 3, 1285–1289 (2012).
17. Khare, C. P. Indian Herbal Remedies: Rational Western Therapy, Ayurvedic, and Other Traditional Usage. Botany (Springer, 2004).
18. Gujwaik, P. D., Ahmed, M. L., Khalid, M. S. & Swamy, P. Antiinflammatory activity of Madhuca longiflora seed saponin mixture. Pharm. Biol. 47, 592–597. [https://doi.org/10.1080/13880909202513] (2009).
19. Chou, M. M. et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloproteinase-9, and cartilage damage in arthritis. Exp. Biol. Med. (Maywood) 230, 255–262. [https://doi.org/10.1177/153692830523000405] (2005).
20. Patil, M. V. K., Kandhare, A. D. & Rhsie, S. D. Anti-arthritic and anti-inflammatory activity of *Xanthium strumarium* L. ethanolic extract in Freund’s complete adjuvant induced arthritis. Biomed. Aging Pathol. 2, 6–15 (2012).
21. Kandhare, A. D., Raygude, K. S., Ghosh, P., Ghule, A. E. & Bodhankar, S. L. Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 83, 650–659. [https://doi.org/10.1016/j.fitote.2012.01.010] (2012).
22. Kandhare, A. D., Raygude, K. S., Ghosh, P., Ghule, A. E. & Bodhankar, S. L. Therapeutic role of curcumin in prevention of biochemical and behavioral aberration induced by alcoholic neuropathy in laboratory animals. Neurosci. Lett. 511, 18–22. [https://doi.org/10.1016/j.neulet.2012.01.019] (2012).
23. Vetal, S., Bodhankar, S. L., Mohan, V. & Thakurdesai, P. A. Anti-inflammatory and anti-arthritic activity of type-A procyanidine polyphenols from bark of Cinnamomum zeylanicum in rats. Food Sci. Human Wellness 2, 59–67. https://doi.org/10.1016/j.fshw.2013.03.003 (2013).

24. Kandhare, A. D., Ghosh, P. & Bodhankar, S. L. Naringin, a flavanone glycoside, promotes angiogenesis and inhibits endothelial apoptosis through modulation of inflammatory and growth factor expression in diabetic foot ulcer in rats. Chem. Biol. Interact. 219, 101–112. https://doi.org/10.1016/j.cbi.2014.05.012 (2014).

25. Seewoos, S. et al. A multiparameter approach to monitor disease activity in collagen-induced arthritis. Arthritis Res. Ther. 12, R160. https://doi.org/10.1186/ar3119 (2010).

26. Haleagrahara, N. et al. Therapeutic effect of quercetin in collagen-induced arthritis. Biomed. Pharmacother. 90, 38–46. https://doi.org/10.1016/j.biopha.2017.03.026 (2017).

27. Gardi, C. et al. Quercetin reduced inflammation and increased antioxidant defense in rat adjuvant arthritis. Arch. Biochem. Biophys. 583, 150–157. https://doi.org/10.1016/j.abb.2015.08.008 (2015).

28. McPhee, S. et al. Prophylactic and therapeutic effects of Mytilus edulis fatty acids on adjuvant-induced arthritis in male Wistar rats. Prostaglandins Leukot Essent Fatty Acids 82, 97–103. https://doi.org/10.1016/j.plefa.2009.12.003 (2010).

29. Zhang, G., Kandhare, A. D., Mukherjee, A. A., Bodhankar, S. L. & Yin, H. Ameliorative effect of morin, a plant flavonoid against Freund's complete adjuvant-induced polyarthritis in rats. Pharmacogen. Mag. 15, 43. https://doi.org/10.4103/pm.pm_351_18 (2019).

30. Radovanovic-Dinic, B., Tesic-Rajkovic, S., Zivkovic, V. & Grgov, S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol. Int. 38, 715–724. https://doi.org/10.1007/s00298-018-4021-5 (2018).

31. Kandhare, A. D., Shivakumar, V., Rajmane, A., Ghosh, P. & Bodhankar, S. L. Evaluation of the neuroprotective effect of chrysin via modulation of endogenous biomarkers in a rat model of spinal cord injury. J. Nat. Med. 68, 586–603. https://doi.org/10.1007/s11418-014-0840-1 (2014).

32. Visnagri, A. et al. Elucidation of ameliorative effect of Co-enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers. Biomed. Aging Pathol. 2, 157–172 (2012).

33. Chen, X., Zhang, C., Wang, X. & Huo, S. Juglans inhibits IL-1beta-induced inflammation in human chondrocytes. Artif. Cells Nanomed. Biotechnol. 47, 3614–3620. https://doi.org/10.1080/21691401.2019.1657877 (2019).

34. Giridharan, S. & Srinivasan, M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J. Inflamm. Res. 11, 407–419. https://doi.org/10.2147/JIR.S140188 (2018).

35. Chang, X. et al. Protective effect of apigenin on Freund's complete adjuvant-induced arthritis in rats via inhibiting P2X7/NF-κB pathway. Chem. Biol. Interact. 236, 41–46 (2015).

36. De Marchi, E. et al. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38, 3636–3650. https://doi.org/10.1038/s41388-019-0684-y (2019).

37. Maksimović, Z. & Samardžić, S. Herbal medicinal products in the treatment of osteoarthritis. Osteoarthritis Biomark. Treat. 1–18 (2018).

Author contributions
Y.T.: Experimental studies, Data acquisition, Manuscript editing, Manuscript review. D.X.: Concepts, Design, Manuscript preparation, Manuscript editing, Manuscript review. W.G.: Concepts, Design, Statistical analysis, Manuscript review. H.W.: Concepts, Design, Manuscript preparation, Manuscript editing, Manuscript review. Y.Q.: Concepts, Design, Statistical analysis, Manuscript review.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-97474-2.

Correspondence and requests for materials should be addressed to Y.Q.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021